Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition

Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Endocr Soc
Auteurs principaux: Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka
Format: Artigo
Langue:Inglês
Publié: Endocrine Society 2018
Sujets:
Brief Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://ncbi.nlm.nih.gov/pubmed/29942923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires